Drugs / zabilugene almadenorepvec
zabilugene almadenorepvec
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT05057715 | Mar 2022 → Sep 2038 expected | malignant epithelial tumor of ovary, pancreatic adenocarcinoma | University of Pennsylvania | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03799744 | Mar 2019 → Jan 2023 | head and neck squamous cell carcinoma, metastatic squamous cell carcinoma | Catalan Institute of Oncology | Unknown | No outcome recorded |
| Phase 1 | NCT02045589 | Jan 2014 → Oct 2016 | pancreatic adenocarcinoma | Theriva Biologics SL | Completed | No outcome recorded |
| Phase 1 | NCT02045602 | Jan 2014 → May 2019 | metastatic neoplasm, pancreatic adenocarcinoma | Theriva Biologics SL | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07701486 | Aug 2026 → Aug 2027 expected | pancreatic ductal adenocarcinoma | Theriva Biologics SL | Not yet recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05673811 | Jan 2023 → Mar 2025 | metastatic malignant neoplasm, pancreatic adenocarcinoma | Theriva Biologics SL | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT03284268 | Sep 2017 → Jun 2024 | retinoblastoma | Fundació Sant Joan de Déu | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | zabilugene almadenorepvec | “VCN-01 oncolytic adenovirus (zabilugene almadenorepvec)” NCT07701486 ↗ |
| Known as | VCN-01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05673811 ↗ |
| Known as | Zabilugen almadenorepvec | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068319 ↗ |
| Route | Intravenous | “single intravenous injection of VCN-01” NCT02045602 ↗ |